Denali Therapeutics Inc. Expected to Post Q1 2024 Earnings of ($0.75) Per Share (NASDAQ:DNLI)

Denali Therapeutics Inc. (NASDAQ:DNLIGet Rating) – Wedbush issued their Q1 2024 earnings estimates for shares of Denali Therapeutics in a report released on Friday, May 6th. Wedbush analyst L. Chico anticipates that the company will post earnings of ($0.75) per share for the quarter.

Several other equities analysts also recently issued reports on DNLI. The Goldman Sachs Group reduced their price target on shares of Denali Therapeutics from $114.00 to $98.00 and set a “buy” rating for the company in a report on Monday, March 7th. TheStreet downgraded shares of Denali Therapeutics from a “c-” rating to a “d” rating in a report on Wednesday, March 2nd. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Denali Therapeutics has a consensus rating of “Buy” and an average price target of $81.67.

Shares of DNLI opened at $23.05 on Monday. Denali Therapeutics has a 1 year low of $22.52 and a 1 year high of $79.70. The company has a market cap of $2.83 billion, a price-to-earnings ratio of -9.85 and a beta of 1.90. The firm has a fifty day moving average of $30.28 and a 200-day moving average of $37.96.

Denali Therapeutics (NASDAQ:DNLIGet Rating) last released its quarterly earnings data on Thursday, May 5th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.06). The business had revenue of $42.10 million during the quarter, compared to analyst estimates of $33.32 million. Denali Therapeutics had a negative return on equity of 28.13% and a negative net margin of 344.79%. The business’s revenue for the quarter was up 432.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.58) EPS.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Los Angeles Capital Management LLC raised its holdings in Denali Therapeutics by 2.8% during the 1st quarter. Los Angeles Capital Management LLC now owns 42,252 shares of the company’s stock worth $1,359,000 after buying an additional 1,160 shares during the period. Envestnet Asset Management Inc. raised its holdings in Denali Therapeutics by 16.8% during the 1st quarter. Envestnet Asset Management Inc. now owns 33,358 shares of the company’s stock worth $1,073,000 after buying an additional 4,795 shares during the period. State of New Jersey Common Pension Fund D raised its holdings in Denali Therapeutics by 29.0% during the 1st quarter. State of New Jersey Common Pension Fund D now owns 76,931 shares of the company’s stock worth $2,475,000 after buying an additional 17,313 shares during the period. DekaBank Deutsche Girozentrale raised its holdings in Denali Therapeutics by 9.9% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 59,800 shares of the company’s stock worth $1,938,000 after buying an additional 5,400 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Denali Therapeutics by 4.1% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,390 shares of the company’s stock valued at $366,000 after purchasing an additional 446 shares during the period. Hedge funds and other institutional investors own 72.32% of the company’s stock.

In other Denali Therapeutics news, COO Alexander O. Schuth sold 1,423 shares of the business’s stock in a transaction dated Wednesday, February 9th. The shares were sold at an average price of $37.10, for a total value of $52,793.30. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Marc Tessier-Lavigne sold 20,000 shares of the business’s stock in a transaction dated Wednesday, March 23rd. The stock was sold at an average price of $33.83, for a total transaction of $676,600.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 43,210 shares of company stock worth $1,496,386. 17.00% of the stock is owned by company insiders.

About Denali Therapeutics (Get Rating)

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease.

Further Reading

Earnings History and Estimates for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.